Related Experiment Video

Updated: May 24, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

Eric Judd1, Edgar A Jaimes

  • 1University of Alabama at Birmingham, Vascular Biology and Hypertension Program, 115 Community Health Services Building, 933 19th Street South, Birmingham, AL, USA.

Expert Review of Cardiovascular Therapy
|March 7, 2012
PubMed

Insights

Achieving target blood pressure often requires multiple antihypertensive medications. Single-pill triple combinations, like aliskiren, amlodipine, and hydrochlorothiazide, offer improved efficacy and adherence for patients with hypertension.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a major risk factor for cardiovascular morbidity and mortality.
  • Lowering blood pressure effectively reduces cardiovascular risk.
  • Most patients require multiple antihypertensive medications to achieve blood pressure goals.

Purpose of the Study:

  • To evaluate the safety and efficacy of a single-pill triple combination therapy.
  • To assess the utility of aliskiren, amlodipine, and hydrochlorothiazide in patients with resistant hypertension.

Main Methods:

  • Review of clinical trial data on antihypertensive medication efficacy.
  • Analysis of studies investigating single-pill triple combination therapies.
  • Assessment of combination therapy with aliskiren, amlodipine, and hydrochlorothiazide.

Main Results:

  • Single-pill triple combinations demonstrate increased efficacy and adherence compared to dual- and mono-therapy.
  • The combination of aliskiren, amlodipine, and hydrochlorothiazide is effective in lowering blood pressure.
  • This triple combination is safe for patients who have not achieved goal blood pressure with dual therapy.

Conclusions:

  • Single-pill triple combination therapy is a viable strategy for managing hypertension.
  • Aliskiren, amlodipine, and hydrochlorothiazide combination offers a rational and effective treatment option.
  • This regimen improves blood pressure control in patients refractory to dual therapy.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...